George Ansstas
Washington University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name George Ansstas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:43 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07715734 · Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell CarcinomaWashington University School of Medicine · not yet recruiting · Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma · principal investigator
- Ph2NCT05060003 · Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following ResectionWashington University School of Medicine · terminated · Stage II Melanoma · principal investigator
- Ph2NCT04318717 · Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal MelanomaWashington University School of Medicine · suspended · Mucosal Melanoma of the Head and Neck · principal investigator
- Ph2NCT03903640 · Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain MetastasisWashington University School of Medicine · terminated · Melanoma With Brain Metastasis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:43 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:43 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- 774 citationsRCR 93.8
- Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.Neuro Oncol · 2022489 citationsRCR 33.3
- 417 citationsRCR 37.4
- Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.J Clin Oncol · 2023102 citationsRCR 9.7
- Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.Am J Hematol · 201968 citationsRCR 2.2
- BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.Clin Cancer Res · 202261 citationsRCR 3.9
- A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.J Am Acad Dermatol · 202557 citationsRCR 13.3
- Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.J Neurooncol · 201846 citationsRCR 1.8
- A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma.Int J Radiat Oncol Biol Phys · 202435 citationsRCR 4.3
- Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.J Immunother Cancer · 202513 citationsRCR 3.2